<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2008-03-19" updated="2019-12-02">
  <drugbank-id primary="true">DB06235</drugbank-id>
  <drugbank-id>DB13081</drugbank-id>
  <name>Vadimezan</name>
  <description/>
  <cas-number>117570-53-3</cas-number>
  <unii>0829J8133H</unii>
  <average-mass>282.2907</average-mass>
  <monoisotopic-mass>282.089208936</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A4101</ref-id>
        <pubmed-id>15800918</pubmed-id>
        <citation>Zhao L, Ching LM, Kestell P, Kelland LR, Baguley BC: Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer. 2005 Aug 20;116(2):322-6.</citation>
      </article>
      <article>
        <ref-id>A4102</ref-id>
        <pubmed-id>18095916</pubmed-id>
        <citation>McKeage MJ: The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin Investig Drugs. 2008 Jan;17(1):23-9.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L78</ref-id>
        <title>Link</title>
        <url>http://www.antisoma.com/asm/media/press/pr2007/2007-08-22/</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in solid tumors, lung cancer, ovarian cancer, and prostate cancer.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>ASA404 (DMXAA) is a small-molecule vascular disrupting agent which targets the blood vessels that nourish tumours. The proposed mechanism of action for ASA404 is directly increasing  permeability of the tumor's endothelial cells. Vasoactive mediators such as tumor necrosis factor (TNF) may also be implicated. Increased permeability of tumor cell vasculature may allow increased permeation of anticancer treatments such as cytotoxic drugs, antibodies, drug conjugates and gene therapy.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as xanthones. These are polycyclic aromatic compounds containing a xanthene moiety conjugated to a ketone group at carbon 9. Xanthene is a tricyclic compound made up of two benzene rings linearly fused to each other through a pyran ring.</description>
    <direct-parent>Xanthones</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Benzopyrans</class>
    <subclass>1-benzopyrans</subclass>
    <alternative-parent>Benzenoids</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Chromones</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Pyranones and derivatives</alternative-parent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Chromone</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Pyran</substituent>
    <substituent>Pyranone</substituent>
    <substituent>Xanthone</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002001</drugbank-id>
      <name>Vadimezan sodium</name>
      <unii>C35T92HIZM</unii>
      <cas-number>129095-08-5</cas-number>
      <inchikey>CUHSZPRXKQDLCJ-UHFFFAOYSA-M</inchikey>
      <average-mass>304.277</average-mass>
      <monoisotopic-mass>304.07115318</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">(5,6-dimethyl-9-oxoxanthen-4-yl)acetic acid</synonym>
    <synonym language="english" coder="">5,6-Dimethyl-9-oxo-9H-xanthene-4-acetic acid</synonym>
    <synonym language="english" coder="">5,6-Dimethylxanthenone-4-acetic acid</synonym>
    <synonym language="english" coder="">5,6-Dimethylxanthenoneacetic acid</synonym>
    <synonym language="english" coder="">5,6-MeXAA</synonym>
    <synonym language="english" coder="">Dimethyloxoxanthene acetic acid</synonym>
    <synonym language="english" coder="">DMXAA</synonym>
    <synonym language="french" coder="inn">Vadim√©zan</synonym>
    <synonym language="english/spanish" coder="inn">Vadimezan</synonym>
    <synonym language="latin" coder="inn">Vadimezanum</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>UGT1A9 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>UGT2B7 substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Xanthenes</category>
      <mesh-id>D014966</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>4lol</pdb-entry>
    <pdb-entry>4qxo</pdb-entry>
    <pdb-entry>4qxp</pdb-entry>
    <pdb-entry>4qxq</pdb-entry>
    <pdb-entry>4qxr</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The serum concentration of Vadimezan can be increased when it is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The serum concentration of Vadimezan can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The serum concentration of Vadimezan can be decreased when it is combined with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The serum concentration of Vadimezan can be decreased when it is combined with Teriflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The serum concentration of Vadimezan can be increased when it is combined with Abiraterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The metabolism of Vadimezan can be increased when combined with Cyproterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The metabolism of Vadimezan can be increased when combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The metabolism of Vadimezan can be increased when combined with Primidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The metabolism of Vadimezan can be increased when combined with Rifampicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00201</drugbank-id>
      <name>Caffeine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Moxifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Lidocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00379</drugbank-id>
      <name>Mexiletine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Mexiletine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Imipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Alosetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Gatifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Simeprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Lobeglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Pazufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The serum concentration of Vadimezan can be decreased when it is combined with Osimertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The serum concentration of Vadimezan can be increased when it is combined with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The metabolism of Vadimezan can be increased when combined with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00011</drugbank-id>
      <name>Interferon alfa-n1</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00018</drugbank-id>
      <name>Interferon alfa-n3</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00033</drugbank-id>
      <name>Interferon gamma-1b</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Interferon gamma-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00034</drugbank-id>
      <name>Interferon alfa-2a, Recombinant</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Interferon alfa-2a, Recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00060</drugbank-id>
      <name>Interferon beta-1a</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Interferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00068</drugbank-id>
      <name>Interferon beta-1b</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Interferon beta-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00069</drugbank-id>
      <name>Interferon alfacon-1</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Interferon alfacon-1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Interferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Ticlopidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Valproic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Omeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Nitric Oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Pefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00553</drugbank-id>
      <name>Methoxsalen</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Methoxsalen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Efavirenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Dexmedetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Thiabendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Tranylcypromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Nalidixic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Estradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Rosoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Cinoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Ondansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Isoniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Lomefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Selegiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Norfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Tegaserod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Resveratrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Estrone sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Pirfenidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05258</drugbank-id>
      <name>Interferon alfa</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Interferon alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05396</drugbank-id>
      <name>Albinterferon Alfa-2B</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Albinterferon Alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05990</drugbank-id>
      <name>Obeticholic acid</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Obeticholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Garenoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Dapagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Nemonoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Safinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06803</drugbank-id>
      <name>Niclosamide</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Niclosamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Flumequine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Peginterferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11198</drugbank-id>
      <name>Peppermint oil</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Peppermint oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11404</drugbank-id>
      <name>Enrofloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Enrofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11443</drugbank-id>
      <name>Orbifloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Orbifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11491</drugbank-id>
      <name>Sarafloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Sarafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11511</drugbank-id>
      <name>Difloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Difloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Rifamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Prulifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11994</drugbank-id>
      <name>Diacerein</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Diacerein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Triclabendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Dihydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13174</drugbank-id>
      <name>Rhein</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Rhein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13261</drugbank-id>
      <name>Sitafloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Sitafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Oxolinic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13772</drugbank-id>
      <name>Rufloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Rufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Enasidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Estradiol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Estradiol benzoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Estradiol cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Estradiol dienanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Estradiol valerate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13975</drugbank-id>
      <name>Black cohosh</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Black cohosh.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14999</drugbank-id>
      <name>Human interferon beta</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Human interferon beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15119</drugbank-id>
      <name>Ropeginterferon alfa-2b</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Ropeginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15131</drugbank-id>
      <name>Interferon alfa-2c</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Interferon alfa-2c.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06442</drugbank-id>
      <name>Avasimibe</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Avasimibe.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Cannabidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Cepeginterferon alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Medical Cannabis.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Nabiximols.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14635</drugbank-id>
      <name>Curcumin sulfate</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Curcumin sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Betaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Carmustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Theophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Conjugated estrogens.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Ropivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Zolmitriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Acetaminophen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Amitriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Chlorzoxazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Mirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Tacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Triamterene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Zolpidem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00442</drugbank-id>
      <name>Entecavir</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Entecavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Nabumetone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Flutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Albendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Mephenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Nortriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Cinnarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Clonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Diclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Guanabenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Pemetrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Tizanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Riluzole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Zileuton.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Clopidogrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Etoposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Acyclovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Naproxen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Pentoxifylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Perphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Dacarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Terbinafine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Ranitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Ethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Cyclobenzaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Maprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Ramelteon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Azathioprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Frovatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Levobupivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01012</drugbank-id>
      <name>Cinacalcet</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Cinacalcet.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01056</drugbank-id>
      <name>Tocainide</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Tocainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Praziquantel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Melatonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01094</drugbank-id>
      <name>Hesperetin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Hesperetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Doxepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Cilostazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Domperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01191</drugbank-id>
      <name>Dexfenfluramine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Dexfenfluramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Aminophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Clomipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Dasatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01303</drugbank-id>
      <name>Oxtriphylline</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Oxtriphylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Rasagiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Temafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Theobromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Aminophenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01482</drugbank-id>
      <name>Fenethylline</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Fenethylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Bromazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Thiothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01667</drugbank-id>
      <name>8-azaguanine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with 8-azaguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02134</drugbank-id>
      <name>Xanthine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Xanthine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02489</drugbank-id>
      <name>9-Methylguanine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with 9-Methylguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02568</drugbank-id>
      <name>Peldesine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Peldesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Phenacetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04076</drugbank-id>
      <name>Hypoxanthine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Hypoxanthine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04356</drugbank-id>
      <name>9-Deazaguanine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with 9-Deazaguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Flunarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Lorcaserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Lofexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Mianserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Eltrombopag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06479</drugbank-id>
      <name>Propentofylline</name>
      <description>The metabolism of Propentofylline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The metabolism of Pazopanib can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>The metabolism of Agomelatine can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The metabolism of Axitinib can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The metabolism of Bendamustine can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The metabolism of Benzyl alcohol can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06774</drugbank-id>
      <name>Capsaicin</name>
      <description>The metabolism of Capsaicin can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The metabolism of (R)-warfarin can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>The metabolism of Perampanel can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The metabolism of Pomalidomide can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>The metabolism of Tasimelteon can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>The metabolism of Zotepine can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The metabolism of Tegafur can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The metabolism of Doxofylline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The metabolism of Propacetamol can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09290</drugbank-id>
      <name>Ramosetron</name>
      <description>The metabolism of Ramosetron can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11919</drugbank-id>
      <name>6-O-benzylguanine</name>
      <description>The metabolism of 6-O-benzylguanine can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11967</drugbank-id>
      <name>Binimetinib</name>
      <description>The metabolism of Binimetinib can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The metabolism of Voxilaprevir can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The metabolism of Rucaparib can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>The metabolism of Lisofylline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12531</drugbank-id>
      <name>Lobucavir</name>
      <description>The metabolism of Lobucavir can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12926</drugbank-id>
      <name>Cafedrine</name>
      <description>The metabolism of Cafedrine can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>The metabolism of Theodrenaline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13203</drugbank-id>
      <name>Bamifylline</name>
      <description>The metabolism of Bamifylline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13449</drugbank-id>
      <name>Proxyphylline</name>
      <description>The metabolism of Proxyphylline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13573</drugbank-id>
      <name>Acefylline</name>
      <description>The metabolism of Acefylline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13592</drugbank-id>
      <name>Etamiphylline</name>
      <description>The metabolism of Etamiphylline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13634</drugbank-id>
      <name>Pentifylline</name>
      <description>The metabolism of Pentifylline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13812</drugbank-id>
      <name>Bufylline</name>
      <description>The metabolism of Bufylline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>The metabolism of Bromotheophylline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14132</drugbank-id>
      <name>8-chlorotheophylline</name>
      <description>The metabolism of 8-chlorotheophylline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Tamoxifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The metabolism of Istradefylline can be decreased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Metoclopramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04889</drugbank-id>
      <name>Bicifadine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Bicifadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05708</drugbank-id>
      <name>GTS-21</name>
      <description>The metabolism of Vadimezan can be decreased when combined with GTS-21.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Flecainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Enoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00549</drugbank-id>
      <name>Zafirlukast</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Zafirlukast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05488</drugbank-id>
      <name>Technetium Tc-99m ciprofloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Technetium Tc-99m ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14025</drugbank-id>
      <name>Clinafloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Clinafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14029</drugbank-id>
      <name>Furafylline</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Furafylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The metabolism of Vadimezan can be increased when combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The metabolism of Vadimezan can be increased when combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The metabolism of Vadimezan can be increased when combined with Adalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The metabolism of Vadimezan can be increased when combined with Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The metabolism of Vadimezan can be increased when combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The metabolism of Vadimezan can be increased when combined with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The metabolism of Vadimezan can be increased when combined with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The metabolism of Vadimezan can be increased when combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The metabolism of Vadimezan can be increased when combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The metabolism of Vadimezan can be increased when combined with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The metabolism of Vadimezan can be increased when combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The metabolism of Vadimezan can be increased when combined with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The metabolism of Vadimezan can be increased when combined with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The metabolism of Vadimezan can be increased when combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The metabolism of Vadimezan can be increased when combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Flunitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Dovitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06777</drugbank-id>
      <name>Chenodeoxycholic acid</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Chenodeoxycholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The metabolism of Vadimezan can be increased when combined with Phenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15066</drugbank-id>
      <name>Givosiran</name>
      <description>The serum concentration of Vadimezan can be increased when it is combined with Givosiran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Trovafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Viloxazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13823</drugbank-id>
      <name>Pipemidic acid</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Pipemidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00238</drugbank-id>
      <name>Nevirapine</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Nevirapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin human</name>
      <description>The metabolism of Vadimezan can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>The metabolism of Vadimezan can be increased when combined with Insulin lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>The metabolism of Vadimezan can be increased when combined with Insulin glargine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin pork</name>
      <description>The metabolism of Vadimezan can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00170</drugbank-id>
      <name>Menadione</name>
      <description>The metabolism of Vadimezan can be increased when combined with Menadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00388</drugbank-id>
      <name>Phenylephrine</name>
      <description>The metabolism of Vadimezan can be increased when combined with Phenylephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00400</drugbank-id>
      <name>Griseofulvin</name>
      <description>The metabolism of Vadimezan can be increased when combined with Griseofulvin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The metabolism of Vadimezan can be increased when combined with Secobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>The metabolism of Vadimezan can be increased when combined with Streptozocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The metabolism of Vadimezan can be increased when combined with Meperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00607</drugbank-id>
      <name>Nafcillin</name>
      <description>The metabolism of Vadimezan can be increased when combined with Nafcillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00745</drugbank-id>
      <name>Modafinil</name>
      <description>The metabolism of Vadimezan can be increased when combined with Modafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>The metabolism of Vadimezan can be increased when combined with Rabeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>The metabolism of Vadimezan can be increased when combined with Insulin aspart.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>The metabolism of Vadimezan can be increased when combined with Insulin detemir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>The metabolism of Vadimezan can be increased when combined with Insulin glulisine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The metabolism of Vadimezan can be increased when combined with Fosphenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>The metabolism of Vadimezan can be increased when combined with NN344.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06413</drugbank-id>
      <name>Armodafinil</name>
      <description>The metabolism of Vadimezan can be increased when combined with Armodafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06732</drugbank-id>
      <name>beta-Naphthoflavone</name>
      <description>The metabolism of Vadimezan can be increased when combined with beta-Naphthoflavone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>The metabolism of Vadimezan can be increased when combined with Insulin degludec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The metabolism of Vadimezan can be increased when combined with Insulin peglispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>The metabolism of Vadimezan can be increased when combined with Insulin tregopil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The metabolism of Vadimezan can be increased when combined with Pitolisant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>The metabolism of Insulin beef can be increased when combined with Vadimezan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Phenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Mefenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Diflunisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Niflumic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Regorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Isavuconazole.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.06</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.25e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.62</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>vadimezan</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>282.2907</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>282.089208936</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC1=C(C)C2=C(C=C1)C(=O)C1=CC=CC(CC(O)=O)=C1O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C17H14O4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>XGOYIMQSIKSOBS-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>63.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>78.21</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>29.37</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>3.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-7.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>75934</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>123964</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827766</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>110486</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>1YE</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Vadimezan</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL71263</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB06235</drugbank-id>
        <name>Vadimezan</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01775</drugbank-id>
        <name>6-Hydroxy-MXAA</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002433</drugbank-id>
          <name>Cytochrome P450 1A2</name>
          <uniprot-id>P05177</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes>
    <enzyme position="1">
      <id>BE0003538</id>
      <name>UDP-glucuronosyltransferase 1-9</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17720</ref-id>
            <pubmed-id>12201491</pubmed-id>
            <citation>Zhou S, Kestell P, Baguley BC, Paxton JW: 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Invest New Drugs. 2002 Aug;20(3):281-95.</citation>
          </article>
          <article>
            <ref-id>A17721</ref-id>
            <pubmed-id>12487149</pubmed-id>
            <citation>Zhou S, Kestell P, Paxton JW: Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug Metab Rev. 2002 Nov;34(4):751-90.</citation>
          </article>
          <article>
            <ref-id>A17722</ref-id>
            <pubmed-id>9000569</pubmed-id>
            <citation>Miners JO, Valente L, Lillywhite KJ, Mackenzie PI, Burchell B, Baguley BC, Kestell P: Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res. 1997 Jan 15;57(2):284-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O60656" source="Swiss-Prot">
        <name>UDP-glucuronosyltransferase 1-9</name>
        <general-function>Retinoic acid binding</general-function>
        <specific-function>UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.</specific-function>
        <gene-name>UGT1A9</gene-name>
        <locus>2q37</locus>
        <cellular-location>Microsome</cellular-location>
        <transmembrane-regions>488-504</transmembrane-regions>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>7.96</theoretical-pi>
        <molecular-weight>59940.495</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12541</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S55985</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>7690346</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O60656</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>UD19_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.1.17</synonym>
          <synonym>GNT1</synonym>
          <synonym>lugP4</synonym>
          <synonym>UDP-glucuronosyltransferase 1-I</synonym>
          <synonym>UDP-glucuronosyltransferase 1A9</synonym>
          <synonym>UDPGT 1-9</synonym>
          <synonym>UGT-1I</synonym>
          <synonym>UGT1</synonym>
          <synonym>UGT1I</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006817|UDP-glucuronosyltransferase 1-9
MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLILRGHEVVVVMP
EVSWQLGRSLNCTVKTYSTSYTLEDLDREFKAFAHAQWKAQVRSIYSLLMGSYNDIFDLF
FSNCRSLFKDKKLVEYLKESSFDAVFLDPFDNCGLIVAKYFSLPSVVFARGILCHYLEEG
AQCPAPLSYVPRILLGFSDAMTFKERVRNHIMHLEEHLLCHRFFKNALEIASEILQTPVT
EYDLYSHTSIWLLRTDFVLDYPKPVMPNMIFIGGINCHQGKPLPMEFEAYINASGEHGIV
VFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGH
PMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDL
ENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTW
YQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012464|UDP-glucuronosyltransferase 1-9 (UGT1A9)
ATGGCTTGCACAGGGTGGACCAGCCCCCTTCCTCTATGTGTGTGTCTGCTGCTGACCTGT
GGCTTTGCCGAGGCAGGGAAGCTACTGGTAGTGCCCATGGATGGGAGCCACTGGTTCACC
ATGAGGTCGGTGGTGGAGAAACTCATTCTCAGGGGGCATGAGGTGGTTGTAGTCATGCCA
GAGGTGAGTTGGCAACTGGGAAGATCACTGAATTGCACAGTGAAGACTTATTCAACTTCA
TATACCCTGGAGGATCTGGACCGGGAGTTCAAGGCTTTTGCCCATGCTCAATGGAAAGCA
CAAGTACGAAGTATATATTCTCTATTAATGGGTTCATACAATGACATTTTTGACTTATTT
TTTTCAAATTGCAGGAGTTTGTTTAAAGACAAAAAATTAGTAGAATACTTAAAGGAGAGT
TCTTTTGATGCAGTGTTTCTCGATCCTTTTGATAACTGTGGCTTAATTGTTGCCAAATAT
TTCTCCCTCCCCTCCGTGGTCTTCGCCAGGGGAATACTTTGCCACTATCTTGAAGAAGGT
GCACAGTGCCCTGCTCCTCTTTCCTATGTCCCCAGAATTCTCTTAGGGTTCTCAGATGCC
ATGACTTTCAAGGAGAGAGTACGGAACCACATCATGCACTTGGAGGAACATTTATTATGC
CACCGTTTTTTCAAAAATGCCCTAGAAATAGCCTCTGAAATTCTCCAAACACCTGTTACG
GAGTATGATCTCTACAGCCACACATCAATTTGGTTGTTGCGAACGGACTTTGTTTTGGAC
TATCCCAAACCCGTGATGCCCAACATGATCTTCATTGGTGGTATCAACTGCCATCAGGGA
AAGCCGTTGCCTATGGAATTTGAAGCCTACATTAATGCTTCTGGAGAACATGGAATTGTG
GTTTTCTCTTTGGGATCAATGGTCTCAGAAATTCCAGAGAAGAAAGCTATGGCAATTGCT
GATGCTTTGGGCAAAATCCCTCAGACAGTCCTGTGGCGGTACACTGGAACCCGACCATCG
AATCTTGCGAACAACACGATACTTGTTAAGTGGCTACCCCAAAACGATCTGCTTGGTCAC
CCGATGACCCGTGCCTTTATCACCCATGCTGGTTCCCATGGTGTTTATGAAAGCATATGC
AATGGCGTTCCCATGGTGATGATGCCCTTGTTTGGTGATCAGATGGACAATGCAAAGCGC
ATGGAGACTAAGGGAGCTGGAGTGACCCTGAATGTTCTGGAAATGACTTCTGAAGATTTA
GAAAATGCTCTAAAAGCAGTCATCAATGACAAAAGTTACAAGGAGAACATCATGCGCCTC
TCCAGCCTTCACAAGGACCGCCCGGTGGAGCCGCTGGACCTGGCCGTGTTCTGGGTGGAG
TTTGTGATGAGGCACAAGGGCGCGCCACACCTGCGCCCCGCAGCCCACGACCTCACCTGG
TACCAGTACCATTCCTTGGACGTGATTGGTTTCCTCTTGGCCGTCGTGCTGACAGTGGCC
TTCATCACCTTTAAATGTTGTGCTTATGGCTACCGGAAATGCTTGGGGAAAAAAGGGCGA
GTTAAGAAAGCCCACAAATCCAAGACCCATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00201</identifier>
            <name>UDPGT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavone metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="2">
      <id>BE0003679</id>
      <name>UDP-glucuronosyltransferase 2B7</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17723</ref-id>
            <pubmed-id>11095582</pubmed-id>
            <citation>Zhou S, Paxton JW, Tingle MD, Kestell P: Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab Dispos. 2000 Dec;28(12):1449-56.</citation>
          </article>
          <article>
            <ref-id>A17724</ref-id>
            <pubmed-id>12781337</pubmed-id>
            <citation>Zhou S, Kestell P, Baguley BC, Paxton JW: Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol. 2003 Jun 1;65(11):1853-65.</citation>
          </article>
          <article>
            <ref-id>A17720</ref-id>
            <pubmed-id>12201491</pubmed-id>
            <citation>Zhou S, Kestell P, Baguley BC, Paxton JW: 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Invest New Drugs. 2002 Aug;20(3):281-95.</citation>
          </article>
          <article>
            <ref-id>A17721</ref-id>
            <pubmed-id>12487149</pubmed-id>
            <citation>Zhou S, Kestell P, Paxton JW: Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug Metab Rev. 2002 Nov;34(4):751-90.</citation>
          </article>
          <article>
            <ref-id>A17722</ref-id>
            <pubmed-id>9000569</pubmed-id>
            <citation>Miners JO, Valente L, Lillywhite KJ, Mackenzie PI, Burchell B, Baguley BC, Kestell P: Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res. 1997 Jan 15;57(2):284-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P16662" source="Swiss-Prot">
        <name>UDP-glucuronosyltransferase 2B7</name>
        <general-function>Glucuronosyltransferase activity</general-function>
        <specific-function>UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol (in vitro).</specific-function>
        <gene-name>UGT2B7</gene-name>
        <locus>4q13</locus>
        <cellular-location>Microsome membrane</cellular-location>
        <transmembrane-regions>493-509</transmembrane-regions>
        <signal-regions>1-23</signal-regions>
        <theoretical-pi>8.45</theoretical-pi>
        <molecular-weight>60694.12</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12554</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J05428</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>340080</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P16662</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>UD2B7_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.1.17</synonym>
          <synonym>3,4-catechol estrogen-specific UDPGT</synonym>
          <synonym>UDP-glucuronosyltransferase 2B9</synonym>
          <synonym>UDPGT 2B7</synonym>
          <synonym>UDPGT 2B9</synonym>
          <synonym>UDPGTh-2</synonym>
          <synonym>UGTB2B9</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012557|UDP-glucuronosyltransferase 2B7
MSVKWTSVILLIQLSFCFSSGNCGKVLVWAAEYSHWMNIKTILDELIQRGHEVTVLASSA
SILFDPNNSSALKIEIYPTSLTKTELENFIMQQIKRWSDLPKDTFWLYFSQVQEIMSIFG
DITRKFCKDVVSNKKFMKKVQESRFDVIFADAIFPCSELLAELFNIPFVYSLSFSPGYTF
EKHSGGFIFPPSYVPVVMSELTDQMTFMERVKNMIYVLYFDFWFEIFDMKKWDQFYSEVL
GRPTTLSETMGKADVWLIRNSWNFQFPHPLLPNVDFVGGLHCKPAKPLPKEMEDFVQSSG
ENGVVVFSLGSMVSNMTEERANVIASALAQIPQKVLWRFDGNKPDTLGLNTRLYKWIPQN
DLLGHPKTRAFITHGGANGIYEAIYHGIPMVGIPLFADQPDNIAHMKARGAAVRVDFNTM
SSTDLLNALKRVINDPSYKENVMKLSRIQHDQPVKPLDRAVFWIEFVMRHKGAKHLRVAA
HDLTWFQYHSLDVIGFLLVCVATVIFIVTKCCLFCFWKFARKAKKGKND</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012558|UDP-glucuronosyltransferase 2B7 (UGT2B7)
ATGTCTGTGAAATGGACTTCAGTAATTTTGCTAATACAACTGAGCTTTTGCTTTAGCTCT
GGGAATTGTGGAAAGGTGCTGGTGTGGGCAGCAGAATACAGCCATTGGATGAATATAAAG
ACAATCCTGGATGAGCTTATTCAGAGAGGTCATGAGGTGACTGTACTGGCATCTTCAGCT
TCCATTCTTTTTGATCCCAACAACTCATCCGCTCTTAAAATTGAAATTTATCCCACATCT
TTAACTAAAACTGAGTTGGAGAATTTCATCATGCAACAGATTAAGAGATGGTCAGACCTT
CCAAAAGATACATTTTGGTTATATTTTTCACAAGTACAGGAAATCATGTCAATATTTGGT
GACATAACTAGAAAGTTCTGTAAAGATGTAGTTTCAAATAAGAAATTTATGAAAAAAGTA
CAAGAGTCAAGATTTGACGTCATTTTTGCAGATGCTATTTTTCCCTGTAGTGAGCTGCTG
GCTGAGCTATTTAACATACCCTTTGTGTACAGTCTCAGCTTCTCTCCTGGCTACACTTTT
GAAAAGCATAGTGGAGGATTTATTTTCCCTCCTTCCTACGTACCTGTTGTTATGTCAGAA
TTAACTGATCAAATGACTTTCATGGAGAGGGTAAAAAATATGATCTATGTGCTTTACTTT
GACTTTTGGTTCGAAATATTTGACATGAAGAAGTGGGATCAGTTTTATAGTGAAGTTCTA
GGAAGACCCACTACATTATCTGAGACAATGGGGAAAGCTGACGTATGGCTTATTCGAAAC
TCCTGGAATTTTCAGTTTCCATATCCACTCTTACCAAATGTTGATTTTGTTGGAGGACTC
CACTGCAAACCTGCCAAACCCCTGCCTAAGGAAATGGAAGACTTTGTACAGAGCTCTGGA
GAAAATGGTGTTGTGGTGTTTTCTCTGGGGTCAATGGTCAGTAACATGACAGAAGAAAGG
GCCAACGTAATTGCATCAGCCCTGGCCCAGATCCCACAAAAGGTTCTGTGGAGATTTGAT
GGGAATAAACCAGATACCTTAGGTCTCAATACTCGGCTCTACAAGTGGATACCCCAGAAT
GACCTTCTAGGTCATCCAAAGACCAGAGCTTTTATAACTCATGGTGGAGCCAATGGCATC
TACGAGGCAATCTACCATGGGATCCCTATGGTGGGGATTCCATTGTTTGCCGATCAACCT
GATAACATTGCTCACATGAAGGCCAGGGGAGCAGCTGTTAGAGTGGACTTCAACACAATG
TCGAGTACAGACTTGCTGAATGCATTGAAGAGAGTAATTAATGATCCTTCATATAAAGAG
AATGTTATGAAATTATCAAGAATTCAACATGATCAACCAGTGAAGCCCCTGGATCGAGCA
GTCTTCTGGATTGAATTTGTCATGCGCCACAAAGGAGCTAAACACCTTCGGGTTGCAGCC
CACGACCTCACCTGGTTCCAGTACCACTCTTTGGATGTGATTGGGTTCCTGCTGGTCTGT
GTGGCAACTGTGATATTTATCGTCACAAAATGTTGTCTGTTTTGTTTCTGGAAGTTTGCT
AGAAAAGCAAAGAAGGGAAAAAATGATTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00201</identifier>
            <name>UDPGT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="3">
      <id>BE0002433</id>
      <name>Cytochrome P450 1A2</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17723</ref-id>
            <pubmed-id>11095582</pubmed-id>
            <citation>Zhou S, Paxton JW, Tingle MD, Kestell P: Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab Dispos. 2000 Dec;28(12):1449-56.</citation>
          </article>
          <article>
            <ref-id>A17724</ref-id>
            <pubmed-id>12781337</pubmed-id>
            <citation>Zhou S, Kestell P, Baguley BC, Paxton JW: Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol. 2003 Jun 1;65(11):1853-65.</citation>
          </article>
          <article>
            <ref-id>A17720</ref-id>
            <pubmed-id>12201491</pubmed-id>
            <citation>Zhou S, Kestell P, Baguley BC, Paxton JW: 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Invest New Drugs. 2002 Aug;20(3):281-95.</citation>
          </article>
          <article>
            <ref-id>A17721</ref-id>
            <pubmed-id>12487149</pubmed-id>
            <citation>Zhou S, Kestell P, Paxton JW: Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug Metab Rev. 2002 Nov;34(4):751-90.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05177" source="Swiss-Prot">
        <name>Cytochrome P450 1A2</name>
        <general-function>Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.</specific-function>
        <gene-name>CYP1A2</gene-name>
        <locus>15q24</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.43</theoretical-pi>
        <molecular-weight>58293.76</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2596</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP1A2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Z00036</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05177</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP1A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYPIA2</synonym>
          <synonym>Cytochrome P(3)450</synonym>
          <synonym>Cytochrome P450 4</synonym>
          <synonym>Cytochrome P450-P3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004778|Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>demethylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron carrier activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular respiration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cadmium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dibenzo-p-dioxin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>methylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocarboxylic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative deethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>porphyrin-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to immobilization stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toxin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>